Linvencorvir
CAS No. 1808248-05-6
Linvencorvir( —— )
Catalog No. M35768 CAS No. 1808248-05-6
Linvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 330 | In Stock |
|
| 5MG | 250 | In Stock |
|
| 10MG | 359 | In Stock |
|
| 25MG | 581 | In Stock |
|
| 50MG | 761 | In Stock |
|
| 100MG | 1014 | In Stock |
|
| 200MG | 1376 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLinvencorvir
-
NoteResearch use only, not for human use.
-
Brief DescriptionLinvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection.
-
DescriptionLinvencorvir is an antiviral agent.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV | Antibiotic
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1808248-05-6
-
Formula Weight598.69
-
Molecular FormulaC29H35FN6O5S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (104.39 mM; Ultrasonic (<60°C)
-
SMILESC(OCC)(=O)C=1[C@@H](NC(=NC1CN2C[C@@]3(N(CC2)C(=O)N(CC(C(O)=O)(C)C)C3)[H])C4=NC=CS4)C5=C(C)C(F)=CC=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 35, No. 4, 2021
molnova catalog
related products
-
?-Thujaplicinol
?-Thujaplicinol, a hydroxylated thujaplicinone isolated from western red cedar heartwood, has antiviral activity, inhibits hepatitis B virus replication by blocking viral ribonuclease H activity, and can be used in the study of viral infections.
-
HAP-12
HAP-12 is a small molecule HBV capsid assembly effector that inhibits HBV DNA replication with EC50 of 0.5 uM.
-
AB-423
AB-423 is a novel potent, class II HBV capsid inhibitor that shows potent inhibition of HBV replication with EC50 of 0.08-0.27 uM, with no significant cytotoxicity (CC50>10 uM).
Cart
sales@molnova.com